弥漫大B细胞淋巴瘤治疗新药格菲妥单抗

Glofitamab for diffuse large B cell lymphoma

弥漫大B细胞淋巴瘤(DLBCL)是一种来源于成熟B细胞的恶性肿瘤,目前其临床治疗以化学治疗为主,但仍有部分患者会在治疗后复发或进展为难治性DLBCL。2023年6月15日,美国FDA批准抗CD3/CD20双特异性单克隆抗体格菲妥单抗上市,为既往接受过二线或二线以上系统治疗后复发或进展为难治性DLBCL的患者提供了新的治疗方案。本文对格菲妥单抗的药理作用、临床研究、安全性及用法用量等进行了简要概述。格菲妥单抗主要通过促进T细胞的活化和增殖,激活T细胞释放肿瘤细胞杀伤蛋白,进而介导B细胞的裂解而发挥治疗DLBCL的作用。临床研究显示,格菲妥单抗对复发或难治性DLBCL具有较好的完全缓解率和客观缓解率,其常见不良反应包括轻/中度细胞因子释放综合征、肌肉骨骼疼痛、皮疹和疲劳,未见明显的药物相互作用。

Diffuse large B cell lymphoma(DLBCL)is a malignant tumor derived from mature B cells.Currently,chemotherapy is still the main clinical treatment.However,some patients experience recurrence or refractory conditions after treatment.On June 15,2023,the FDA approved the marketing of glofitamab,a CD3/CD20 bispecific monoclonal antibody,to provide the new treatment plan for patients with recurrent or refractory DLBCL after receiving 2-line or above systemic treatment.This article reviews pharmacological effects,clinical studies,safety,usage and dosage of glofitamab.Glofitamab mainly plays a therapeutic role in DLBCL by promoting the activation and proliferation of T cells,activating T cells to release tumor cell-killing proteins,and mediating the lysis of B cells.Clinical studies have shown that glofitamab has a better complete and objective response rate for recurrent or refractory DLBCL.Common adverse reactions caused by glofitamab include mild/moderate cytokine release syndrome,musculoskeletal pain,rash,fatigue,and so on,without significant drug interactions.